{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:03:04Z","timestamp":1780372984575,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis Supplements"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.atherosclerosissup.2015.02.034","type":"journal-article","created":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T01:31:13Z","timestamp":1430443873000},"page":"215-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Actual situation of lipoprotein apheresis in Saxony in 2013"],"prefix":"10.1016","volume":"18","author":[{"given":"U.","family":"Emmrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hohenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Julius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.atherosclerosissup.2012.10.003","article-title":"Current situation of lipoprotein apheresis in Saxony","volume":"14","author":"Julius","year":"2013","journal-title":"Atheroscler Suppl"},{"issue":"5","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1567-5688(09)71803-3","article-title":"The Dresden Apheresis Center \u2013 experience with LDL apheresis and immunoadsorption","volume":"10","author":"Julius","year":"2009","journal-title":"Atheroscler Suppl"},{"issue":"Suppl 1","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11789-012-0046-6","article-title":"Current view: indications for extracorporeal lipid apheresis treatment","volume":"7","author":"Schettler","year":"2012","journal-title":"Clin Res Cardiol Suppl"},{"key":"10.1016\/j.atherosclerosissup.2015.02.034_bib4","series-title":"Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Richtlinie Methoden vertrags\u00e4rztliche Versorgung: Apherese bei isolierter Lp(a)- Erh\u00f6hung","author":"Bundesministerium f\u00fcr Gesundheit","year":"2008"},{"issue":"8","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib5","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2013","journal-title":"Lancet Diabetes & Endocrinol"},{"issue":"1","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2217\/clp.12.89","article-title":"Non-HDL cholesterol, ApoB and LDL particle concentration in coronary heart disease risk prediction and treatment","volume":"8","author":"Orringer","year":"2013","journal-title":"Clin Lipidol"},{"issue":"1","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5551\/jat.11.6","article-title":"Non-HDL cholesterol as a measure of atherosclerotic risk","volume":"11","author":"Packard","year":"2004","journal-title":"J Atheroscler Thrombosis"},{"issue":"3","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A meta- analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and Apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.atherosclerosissup.2015.02.034_bib9","series-title":"Kassen\u00e4rztliche Bundesvereinigung. Qualit\u00e4tsbericht","first-page":"47","year":"2013"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0021-9150(00)00371-3","article-title":"The rebound of lipoproteins after LDL- apheresis. Kinetics and estimation of mean lipoprotein levels","volume":"152","author":"Kroon","year":"2000","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.atherosclerosis.2009.06.010","article-title":"Efficacy criteria and cholesterol targets for LDL apheresis","volume":"208","author":"Thompson","year":"2010","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib12","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/clp.13.68","article-title":"Lipoprotein apheresis: an update","volume":"8","author":"Julius","year":"2013","journal-title":"Clin Lipidol"},{"key":"10.1016\/j.atherosclerosissup.2015.02.034_bib13","series-title":"Gew\u00e4hrleistung einer indikationsgerechten Durchf\u00fchrung von Apheresen und Ma\u00dfnahmen zum Datenschutz","author":"Gemeinsamer Bundesausschuss","year":"2013"},{"key":"10.1016\/j.atherosclerosissup.2015.02.034_bib14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jacl.2013.11.002","article-title":"Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy","volume":"8","author":"Vishwanath","year":"2014","journal-title":"Clin Lipidol"},{"key":"10.1016\/j.atherosclerosissup.2015.02.034_bib15","series-title":"Qualit\u00e4tsbericht","first-page":"48","author":"Kassen\u00e4rztliche Bundesvereinigung","year":"2014"},{"key":"10.1016\/j.atherosclerosissup.2015.02.034_bib16","series-title":"Qualit\u00e4tsbericht","first-page":"38","author":"Kassen\u00e4rztliche Bundesvereinigung","year":"2011"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1744-9987.2012.01129.x","article-title":"Why an apheresis center should offer more than one lipoprotein apheresis method","volume":"17","author":"Julius","year":"2013","journal-title":"Ther Apher Dial"},{"issue":"1","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosissup.2012.10.021","article-title":"Lipoprotein apheresis: state of the art and novelties","volume":"14","author":"Stefanutti","year":"2013","journal-title":"Atheroscler Suppl"},{"issue":"1","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.atherosclerosissup.2012.10.035","article-title":"Current standards in diagnosis and therapy of hyperlipoproteinemia","volume":"14","author":"Fischer","year":"2013","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.atherosclerosissup.2015.02.034_bib20","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of Dyslipidaemias","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"issue":"45","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib21","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/1744-9987.12028","article-title":"Treatment of severe genetic Dyslipidemia: where are we going?","volume":"17","author":"Stefanutti","year":"2013","journal-title":"Ther Apher Dial"},{"issue":"23","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib23","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2012.10.037","article-title":"Hyperlipoproteinemia(a): clinical significance and treatment options","volume":"14","author":"Berthold","year":"2013","journal-title":"Atheroscler Suppl"},{"issue":"1","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosissup.2012.10.005","article-title":"Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern","volume":"14","author":"von Dryander","year":"2013","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.atherosclerosissup.2015.02.034_bib26","series-title":"Deutscher Herzbericht","first-page":"40","author":"Deutsche Herzstiftung e.V","year":"2013"},{"issue":"5","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1567-5688(09)71829-X","article-title":"Indication and implementation of lipidapheresis, rheopheresis, or immunoadsorption (Lessons learnt from Germany's largest apheresis center)","volume":"10","author":"Heigl","year":"2009","journal-title":"Atheroscler Suppl"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1744-9987.2009.00747.x","article-title":"Retrospective analysis of longterm lipid apheresis at a single center","volume":"14","author":"Koziolek","year":"2010","journal-title":"Ther Apher Dial"},{"issue":"24","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib29","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Pro(a)- LiFe. Lipoprotein apheresis in patients with maximally tolerated lipid lowering therapy, Lp(a)- hyperlipoproteinemia and progressive cardiovascular disease: prospective observational multicenter study","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ncpcardio1456","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.atherosclerosissup.2015.02.034_bib31","first-page":"1","article-title":"Does regular lipid apheresis in patients with isolated elevated Lipoprotein(a) levels reduce the incidence of cardiovascular events?","author":"Rosada","year":"2013","journal-title":"Artif Organs"},{"issue":"1","key":"10.1016\/j.atherosclerosissup.2015.02.034_bib32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.atherosclerosissup.2012.10.022","article-title":"How will new medications affect the lipoprotein apheresis situation in Germany?","volume":"14","author":"Parhofer","year":"2013","journal-title":"Atheroscler Suppl"}],"container-title":["Atherosclerosis Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568815000355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568815000355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T21:55:44Z","timestamp":1537653344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567568815000355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":32,"alternative-id":["S1567568815000355"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2015.02.034","relation":{},"ISSN":["1567-5688"],"issn-type":[{"value":"1567-5688","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actual situation of lipoprotein apheresis in Saxony in 2013","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis Supplements","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2015.02.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}